Angiogenesis is a crucial step in the growth and metastasis of cancers. The activation of endothelial cells and their further behavior are very critical during angiogenesis. The authors analyze the effect of allyl isothiocyanate (AITC) and phenyl isothiocyanate (PITC) on angiogenesis in an in vitro model using human umbilical vein endothelial cells (HUVECs). AITC and PITC significantly inhibited endothelial cell migration, invasion, and tube formation. 3 H-thymidine proliferation assay showed that AITC and PITC significantly inhibited the proliferation of HUVECs in vitro. The authors also studied the effect of AITC and PITC on the serum cytokine profiles of angiogenesis-induced animals and found that these compounds are highly potent in the downregulation of vascular endothelial growth factor (VEGF) and proinflammatory cytokines such as interleukin (IL)-1β β, IL-6, granulocyte macrophage colony-stimulating factor (GM-CSF), and tumor necrosis factor α α (TNF-α α). Treatment with these compounds showed an elevation in the levels of IL-2 and tissue inhibitor of metalloproteinases (TIMP)-1, which are antiangiogenic factors. Moreover, studies using B16F-10 melanoma cells showed that both AITC and PITC significantly reduced VEGF mRNA expression. These findings suggest that AITC and PITC act as angiogenesis inhibitors through the downregulation of VEGF and proinflammatory cytokines such as IL-1β β, IL-6, GM-CSF, and TNF-α α and upregulation of IL-2 and TIMP.
Angiogenesis, the formation of new blood vessels from preexisting capillaries, is a sequence of events that is fundamental to many physiologic and pathologic processes such as embryonic development, wound healing, menstrual cycle, ischemic diseases, tumor progression, metastasis, and chronic inflammation. 1, 2 Tumor progression and maintenance require the development of an ample blood supply that ensures the delivery of oxygen, nutrients, and growth factors. It has been shown that solid tumors are dependent on the process of angiogenesis for growth beyond 2 to 3 mm in diameter and that increased tumor diameter requires a corresponding increase in vascularization. 3, 4 Angiogenesis is believed to be mediated by proliferation, migration, and remodeling of fully differentiated endothelial cells from preexisting vessels. 5 The initiation of angiogenesis, the angiogenic switch, is dependent on a dynamic balance between proangiogenic and antiangiogenic factors in the immediate environment of endothelial cells. 6 In normal tissues, vascular quiescence is maintained by the dominant influence of endogenous angiogenesis inhibitors over angiogenic stimuli. Tumor angiogenesis, on the other hand, is induced by increased secretion of angiogenic factors and/or downregulation of angiogenesis inhibitors. 7 In the healthy adult, only 0.01% of endothelial cells undergo division, 8 whereas up to 25% of endothelial cells divide in tumor vessels. 9 Moreover, the gene expression pattern of normal endothelial cells differs from endothelial cells in tumors 10 ; for instance, 79 differentially expressed gene products were found in endothelial cells from colon cancer compared with normal endothelial cells. 11 Vascular endothelial growth factor (VEGF) is a key angiogenic factor frequently used by tumors and other tissues to switch on their angiogenic phenotypes. 2 This potent and unique angiogenic protein stimulates capillary formation and has specific mitogenic and chemotactic activity for vascular endothelial cells. 12 VEGF has been shown to induce endothelial cell migration and proliferation and to increase vascular permeability. 13 VEGF also functions as a survival factor for endothelial cells by inhibiting apoptosis. 14 Recent studies have clearly demonstrated that matrix metalloproteinases (MMPs), a family of Zn-dependent endopeptidases that are able to degrade the extracellular matrix (ECM), mediate the release and accumulation of VEGF from the cell matrix 15 and trigger the angiogenic switch by rendering VEGF bioavailable to its receptors. 16 All MMPs can be inhibited by a family of 4 different tissue inhibitor of metalloproteinases (TIMP) proteins. 17 MMPs and TIMPs are always in a state of dynamic balance, and alterations in the MMP-to-TIMP ratio occur with tumor metastasis and angiogenesis. 18 Apart from VEGF, proinflammatory cytokines such as interleukin (IL)-1β, IL-6, tumor necrosis factor α (TNF-α), and granulocyte macrophage colony-stimulating factor (GM-CSF) act as autocrine growth factors for tumor angiogenesis. These cytokines could be prometastatic or proangiogenic, and their deregulated expression directly correlates with the metastatic potential of several human carcinomas. 5 Moreover, altered levels of proinflammatory and proangiogenic factors are observed in various forms of cancer. 19 Since pathological angiogenesis has an important role in tumor progression, the identification of agents that could inhibit tumor-specific angiogenesis is of great value in the prevention of metastasis.
Isothiocyanates (ITCs) occur in cruciferous vegetables as thioglucoside conjugates called glucosinolates. 20 Many ITCs possess protective effects against chemically induced tumors in a variety of animal organs. [21] [22] [23] Phenethyl and benzyl isothiocyanates inhibited carcinogenesis induced by carcinogens such as diethyl nitrosamine, dimethyl benz(a)anthracene (DMBA), or benz(a)pyrene. 24 The mechanism involved in the inhibition of carcinogenesis by ITCs is most likely blocking of the activation of carcinogens through the inactivation of P450 enzymes and activation of phase 2 enzymes. 24 Allyl isothiocyanate (AITC) and phenyl isothiocyanate (PITC) are 2 natural isothiocyanates occurring in Brassica nigra, Lepidum sativum, Wasabia japonica, Raphanus sativus, and Sinapis species. AITC, a hydrolysis product of the glucosinolate sinigrin, has also been shown to strongly induce glutathione-stransferase activity. 25 Earlier studies in our laboratory clearly demonstrated that AITC and PITC inhibited B16F-10 melanoma-induced lung metastasis in C57BL/6 mice. 26 On the basis of these potential anticancer activities of AITC and PITC, in this study, we analyzed their effects on endothelial cell differentiation and proinflammatory cytokine (IL-1β, IL-6, TNF-α, and GM-CSF) production during angiogenesis. The levels of IL-2, VEGF, and TIMP-1 during angiogenesis were also studied.
Materials and Methods

Animals
Four-to 6-week-old male C57BL/6 mice were purchased from the National Institute of Nutrition (Hyderabad, India). The animals were fed with normal mouse chow (Sai Feeds, India) and water ad libitum. All animal experiments were conducted according to the rules and regulations of the Animal Ethics Committee, Government of India.
Cells
Human umbilical vein endothelial cells (HUVECs) were isolated from human umbilical cord vein by collagenase treatment as described by Jaffe et al. 27 The cells were grown in medium 199, supplemented with 20% fetal calf serum (FCS), 100 U/mL penicillin, 100 μg/mL streptomycin, and 2 ng/mL VEGF and fibroblast growth factor (FGF) at 37°C in 5% CO 2 atmosphere. B16F-10 melanoma cells were purchased from the National Centre for Cell Science (Pune, India) and maintained in culture using DMEM with 10% FCS and antibiotics.
Enzyme-Linked Immunosorbent Assay Kits
Highly specific quantitative sandwich enzyme-linked immunosorbent assay (ELISA) kits for mouse IL-1β, IL-6, TNF-α, GM-CSF, and IL-2 were purchased from Pierce Biotechnology (Rockford, Illinois), and the ELISA kits for VEGF and TIMP-1 were purchased from R&D Systems (Minneapolis, Minnesota).
Drug Administration
AITC and PITC were purchased from Sigma (St Louis, Missouri). AITC and PITC were suspended in liquid paraffin oil and administered intraperitoneally at a dosage of 25 μg/dose/animal.
Determination of Cytotoxic Activity of AITC and PITC Toward HUVECs in Culture by MTT Assay
HUVECs were seeded (5000 cells/well) in 96-well, flat-bottom titer plates and incubated for 24 hours at 37°C in 5% CO 2 atmosphere. Different concentrations of AITC and PITC (1-50 μg/mL) were added and incubated further for 48 hours. Before 4-hour completion of incubation, 20 μL MTT (5 mg/mL) was added. 28 The percentage of dead cells was determined using an ELISA plate reader set to record absorbance at 570 nm.
Determination of the Effect of AITC and PITC on Endothelial Cell Proliferation ( 3 H-Thymidine Incorporation Assay)
HUVECs (5000 cells/well) were plated on a 96-well culture plate and incubated at 37°C in 5% CO 2 atmosphere. After 24 hours, various concentrations of AITC and PITC (1, 2, and 5 μg/mL) were added along with 2 ng/mL VEGF and further incubated for 48 hours. 3 H-thymidine was added to each well (1 μCi/ well), and incubation was continued for an additional 18 hours. After incubation, the plates were centrifuged, the culture supernatant was removed, and the cells were washed with phosphate-buffered saline and then treated with ice-cold perchloric acid for 15 minutes. The resulting precipitate was dissolved in 0.5 N NaOH and added to the scintillation fluid, and the radioactivity was counted using a Rack Beta liquid scintillation counter.
Determination of the Effect of AITC and PITC on Endothelial Cell Migration/Motility
HUVECs were seeded into wells of collagen-coated 96-well plates at a density of 2 × 10 5 cells/well and incubated for 24 hours at 37°C in 5% CO 2 atmosphere. A clear area was scraped in the monolayer with a narrow tip by applying suction and then washed with serumfree medium. Different concentrations of AITC and PITC (1, 2, and 5 μg/mL) were added along with 2 ng/mL VEGF and further incubated for 24 hours. After incubation, the cells were fixed in formalin and stained with crystal violet, and photographs were taken (10×). 29
Determination of the Effect of AITC and PITC on Endothelial Cell Invasion
The invasion assay was carried out in modified Boyden chambers as described by Albini et al. 30 The lower compartment of the chamber was filled with serumfree medium 199, and a polycarbonate filter membrane coated with 25 μg type I collagen was placed above this. HUVECs (10 5 cells/150 μL medium 199) were then seeded onto the upper chamber in the presence and absence of AITC and PITC (1, 2, and 5 μg/mL) along with 2 ng/mL VEGF and FGF and incubated at 37°C in 5% CO 2 atmosphere for 10 hours. After incubation, the filters were removed, fixed using methanol, and stained with crystal violet. Cells migrating to the lower surface of the polycarbonate filters were counted under a microscope. The results are expressed as the percentage inhibition of invasion.
Determination of the Effect of AITC and PITC on Endothelial Cell Tube Formation
Thirty microliters of ice-cold matrigel was pipetted into a 96-well, flat-bottom titer plate and kept for 30 minutes at 37°C. HUVECs were seeded into the layer of matrigel at a density of 1 × 10 3 cells/well along with 2 ng/mL VEGF and FGF. Various concentrations of AITC and PITC (1, 2, and 5 μg/mL) were added into the wells and incubated for 48 hours at 37°C in 5% CO 2 atmosphere. After incubation, the cells were fixed, stained with Diff Quick stain, and photographed (20×). 31 Determination of the Effect of AITC and PITC on the Production of IL-1β β, IL-6, TNF-α α, GM-CSF, IL-2, VEGF, and TIMP-1 During Angiogenesis Angiogenesis was induced in 3 groups of C57BL/ 6 mice (8 mice/group) by injecting B16F-10 melanoma cells (10 6 cells/animal) intradermally on the shaven ventral skin of each mouse. 32 Group 1 animals were kept as control animals treated with vehicle only (paraffin oil). Group 2 and 3 animals were treated with 5 consecutive doses of AITC and PITC (25 μg/ dose/animal/d), respectively, starting simultaneously with the tumor challenge. Blood was collected from all groups of animals at 2 time intervals; on the 24th hour and the 9th day after the induction of angiogenesis, serum was separated and used for the estimation of IL-1β, IL-6, TNF-α, GM-CSF, IL-2, VEGF, and TIMP-1 using ELISA kits according to the manufacturer's protocol. 32
Quantitation of Gene-Specific mRNA of VEGF in B16F-10 Melanoma Cells
Quantikine mRNA is a novel method that can be used to quantitate gene-specific mRNA at lower levels. Briefly, B16F-10 cells (10 6 cells) were plated in a 30-mm Petri dish in DMEM with 10% FCS at 37°C in 5% CO 2 atmosphere. Cells were then treated with AITC and PITC (5 μg/mL) for 4 hours. After incubation, the cells were washed, and mRNA preparations were made according to the manufacturer's procedures. mRNAs were hybridized with gene-specific, biotin-labeled detection probes and digoxigenin alkaline-labeled detection probes in a microplate. The hybridization solution was transferred to a streptavidin-coated microplate, and the mRNA probe hybrid was captured. Following a wash to remove the unbound conjugate, a substrate solution was added. An amplifier solution was then added, and the developed color was measured spectrophotometrically at 490 nm. 33
Statistical Analysis
Results are expressed as means ± standard deviations. The statistical analysis was performed using 1-way analysis of variance followed by the Dunnett test.
Results
Cytotoxicity of AITC and PITC Toward HUVECs in Culture by MTT Assay
The cytotoxicity of AITC and PITC toward HUVECs in culture is shown in Table 1 . At concentrations of
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Effect of AITC and PITC on Endothelial Cell Proliferation
The rate of proliferation was determined by 3 Hthymidine incorporation by the DNA of HUVECs. Thymidine incorporation is proportional to the potential of the cells to synthesize DNA. Proliferation was expressed as radioactive counts per minute (cpm). HUVECs showed a very high rate of proliferation (4463.33 ± 112.61 cpm) when stimulated with VEGF. Administration of AITC (53.29%, 2084.82 ± 38.89 cpm) and PITC (45.43%, 2435.33 ± 54.72 cpm) at a concentration of 5 μg/mL significantly inhibited VEGF-induced proliferation of HUVECs. Considerable inhibition of proliferation was also observed when AITC was administered at concentrations of 2 μg/mL (34.02%, 2944.90 ± 42.43 cpm) and 1 μg/mL (12.2%, 3918.80 ± 83.14 cpm). Administration of PITC at 2 μg/mL (3233.33 ± 41.06 cpm) and 1 μg/mL (3939.33 ± 54.01 cpm) produced 27.55% and 11.74% of the inhibition, respectively ( Table 2) .
Effect of AITC and PITC on Endothelial Cell Migration/Motility
The effect of AITC and PITC on the motility of HUVECs is shown in Figure 1 . HUVECs migrated into the clear area when stimulated with VEGF (Figure 1b ). AITC and PITC significantly inhibited the VEGF-induced migration of endothelial cells in a dose-dependent manner. Maximum inhibition of endothelial cell migration was observed at 5 μg/mL (Figure 1e, f) and was similar to that of zero-hour incubation (Figure 1a ). This concentration is nontoxic, as is evident from the MTT assay; hence, the inhibitory effect could not be attributed to cytotoxic activity.
Effect of AITC and PITC on Endothelial Cell Invasion Assay
HUVECs showed a strong invasive property through the collagen matrix when stimulated with VEGF and FGF. Large numbers of cells were found on the lower surface of the polycarbonate, but administration of AITC and PITC produced significant inhibition in the invasion of the collagen matrix by HUVECs in a dosedependent manner. At a concentration of 5 μg/mL, AITC significantly inhibited the invasion of HUVECs by 86.14%, whereas at 2 μg/mL and 1 μg/mL, the inhibition of invasion was found to be 53.77% and 30.5%, respectively (Figure 2b, d, f ). Administration of PITC at a concentration of 5 μg/mL produced 68.99% inhibition of invasion of HUVECs, whereas at 2 μg/mL and 1 μg/mL, the inhibition of invasion was found to be 43.46% and 20.8%, respectively (Figure 2c , e, g).
Effect of AITC and PITC on Endothelial Cell Tube Formation
Treatment of HUVECs with AITC and PITC significantly inhibited tube formation ( Figure 3 ) in a dosedependent manner. Incubation of HUVECs on matrigel with VEGF resulted in the formation of elongated and tube-like structures (Figure 3a ). AITC and PITC effectively reduced the width and length of endothelial tubes at 5 μg/mL (Figure 3f, g) . Human umbilical vein endothelial cells (HUVECs) were incubated with different concentrations (1-50 μg/mL) of allyl isothiocyanate (AITC) and phenyl isothiocyanate (PITC). The percentage of cytotoxicity was determined using an MTT assay. 
Effect of AITC and PITC on VEGF mRNA Expression
A highly elevated level of VEGF mRNA expression was observed in untreated B16F-10 melanoma cells (27.65 ± 0.21 attomoles). Administration of AITC (10.01 attomoles) and PITC (11.77 attomoles) at 5 μg/ml significantly reduced the elevated VEGF mRNA level (P < .001).
Effect of AITC and PITC on Proinflammatory Cytokines of Angiogenesis-Induced Animals
The level of proinflammatory cytokines such as IL-1β, IL-6, TNF-α, and GM-CSF is presented in Table 3 . In control animals, the level of IL-1β in the serum was drastically enhanced 24 hours after tumor challenge (31.74 ± 1.04 pg/mL), which was double when compared with normal levels (16 ± 3.5 pg/mL) and maintained the same level even after 9 days. Although administration of AITC (30.2 ± 1 pg/mL) and PITC (30.6 ± 0.69 pg/mL) did not affect this initial elevation in the serum level of this cytokine on the 24th hour, they effectively reduced the IL-1β level to normal by day 9 (17.59 ± 1.03 pg/mL and 18.21 ± 0.84 pg/mL, respectively, for AITC and PITC) after angiogenesis induction.
The IL-6 level was found to be elevated in the 24hour serum sample of untreated angiogenesisinduced control animals (41.21 ± 3.2 pg/mL) compared with the normal level of 35.65 ± 3.2 pg/mL. On day 9, the level of IL-6 in the serum of control animals was drastically elevated to 326.30 ± 5.58 pg/mL. Administration of AITC (72.33 ± 3.22 pg/mL) and PITC (86.28 ± 2.73 pg/mL) was found to be very effective in checking the drastic enhancement of IL-6 level on the ninth day of tumor inoculation.
Drastic enhancement in the level of serum TNF-α (188.08 ± 7.3 pg/mL) was observed in untreated control animals after 24 hours of angiogenesis induction compared with the normal serum TNF-α level (20 ± 3.2 pg/mL) and was much more elevated on day 9 of tumor challenge (609.5 ± 8.8 pg/mL). Even though the initial enhancement was observed at the 24th hour after tumor inoculation (170.5 ± 8.09 pg/mL and 181.02 ± 7.56 pg/mL, respectively, for AITC and PITC), administration of both AITC and PITC significantly reduced the elevated serum TNF-α level to 144.7 ± 7.85 pg/mL and 156.55 ± 6.45 pg/mL, respectively, after the ninth day of tumor challenge.
The serum GM-CSF level was found to be highly elevated 24 hours after tumor challenge in the untreated control animals (65.42 ± 1.06 pg/mL) compared with the normal level (18 ± 3.1 pg/mL), and by day 9, the level was reduced to 28.62 ± 1.89 pg/mL. AITC and PITC administration showed a reduced level (34.59 ± 1.27 pg/mL and 38.40 ± 2 pg/mL, respectively) compared with the control value, and by day 9, the serum GM-CSF level (23.71 ± 0.39 pg/mL and 26.53 ± 1.05 pg/mL, respectively, for AITC and PITC) was found to be closer to normal values.
VEGF levels showed an elevation in both untreated control (63.97 ± 2.12 pg/mL) and AITCtreated (37.47 ± 0.86 pg/mL) and PITC-treated (41.50 ± 0.78 pg/mL) animals 24 hours after tumor inoculation compared with the normal value of 16 ± 8 pg/mL. This increase was continued in control animals (159.27 ± 4.28 pg/mL) on the ninth day as well, whereas in AITC-and PITC-treated animals, it was only 66.14 ± 1.70 pg/mL and 71.72 ± 0.82 pg/mL, respectively.
Effect of AITC and PITC on IL-2 and TIMP-1 Levels of Angiogenesis-Induced Animals
The lowered levels of IL-2 in the control animals (16.60 ± 0.67 pg/mL) 24 hours after tumor inoculation were normalized by the treatment with AITC (20.23 ± 0.96 pg/mL) and PITC (18.86 ± 1.37 pg/mL). By day 9, administration of AITC (47.14 ± 1.99 pg/mL) and INTEGRATIVE CANCER THERAPIES 6(4); 2007 Blood was collected from the angiogenesis-induced animals at the indicated time points after tumor challenge. Serum was separated by centrifugation, and the cytokine level was estimated by the enzyme-linked immunosorbent assay method. All the values are the mean ± standard deviation. AITC = allyl isothiocyanate; GM-CSF = granulocyte macrophage colony-stimulating factor; IL, interleukin; PITC = phenyl isothiocyanate; TNF-α = tumor necrosis factor α; VEGF = vascular endothelial growth factor. *P < .001 compared with control.
PITC (40.58 ± 2.06 pg/mL) significantly enhanced the level of IL-2 compared with untreated control (18.20 ± 0.55 pg/mL) as well as normal values (23 ± 3.2 pg/mL; Table 4 ). The tissue inhibitor of the metalloprotease level in the serum of normal mouse was 600 ± 36 pg/mL, which was reduced by the induction of tumor cells to 353.48 ± 1.25 pg/mL in the untreated control animals. But administration of AITC (686.83 ± 2.77 pg/mL) and PITC (664.72 ± 3.53 pg/mL) significantly elevated the level of this MMP inhibitor. The ninth-day serum sample also showed a similar TIMP-1 profile in angiogenesis-induced animals. In controls, it was 359.75 ± 1.58 pg/mL (AITC, 804.07 ± 2.54 pg/mL and PITC, 777.58 ± 3.44 pg/mL); treatment could maintain the initial elevation, thereby checking MMPs (Table 4 ).
Discussion
The expansion of tumors is strictly dependent on neoangiogenesis, and the inhibition of vascular supply to tumors can suppress their growth. 6 Because of the role of endothelial cells in several rate-limiting steps of metastasis including angiogenesis, endothelial cell behavior in the presence of different natural as well as synthetic compounds has been the focus of intense investigation. Since AITC and PITC have been reported to inhibit lung metastasis induced by B16F-10 melanoma cells, 26 we investigated the effects of these isothiocyanates on the angiogenic differentiation of endothelial cells using HUVECs.
The process of angiogenesis consists of several steps, which include the stimulation of endothelial cells by growth factors such as VEGF and the subsequent degradation of the ECM by proteolytic enzymes such as MMPs, followed by invasion through the ECM, migration and proliferation of endothelial cells, and finally the formation of new capillary tubes. 34 Activation of endothelial cells is initiated by the binding of proangiogenic factors such as VEGF, basic FGF, plateletderived growth factor, and so on to their receptors expressed on the endothelial cells followed by trans-duction of the angiogenic signaling in the cells. 35 VEGF is regarded as one of the earliest and most important signals to stimulate the multistep cascade of tumor angiogenesis by promoting endothelial cell proliferation and migration. 36 At a molecular level, VEGF reprograms endothelial cell gene expression, leading to an increased expression of a number of different proteins, including MMPs and a number of antiapoptotic factors, such as Bcl-2. 12 In this study, when B16F-10 melanoma cells were introduced intradermally to the mouse, the serum VEGF level was highly elevated as quickly as 24 hours after tumor challenge, while treatment with both AITC and PITC significantly inhibited this elevation of serum VEGF level. This anti-VEGF activity of AITC and PITC may be attributed to their downregulatory action on the VEGF mRNA expression, as is evident from the low-level expression of VEGF mRNA by B16F-10 melanoma cells upon treatment with AITC and PITC.
The levels of proinflammatory cytokines, such as IL-1β, IL-6, TNF-α, and GM-CSF, evaluated in this study are also important in the process of angiogenesis because of their significant proangiogenic effects. IL-1β and TNF-α were shown to increase hypoxiainducible factor (HIF)-1 activity in the human hepatoma cell line HepG2, 37 which in turn causes the release of VEGF. It has been shown that IL-1β and TNFα increase HIF-1α levels by activating nuclear factor κ B. 38 In addition, IL-1β 39 and IL-6 40 have been shown to induce VEGF expression in several malignant and nonmalignant cell lines. IL-6 promotes cervical tumorigenesis by activating VEGF-mediated angiogenesis via a STAT 3 pathway 41 and contributes to a local immunosuppressive effect that protects the tumor cells from the host immune system. 42 GM-CSF is expressed in solid tumors and potentially enhances tumor cell proliferation and migration as well as tumor angiogenesis. 43 It promotes the angiogenic reaction by stimulating endothelial cell proliferation and migration. 43 In our study, we found that the serum levels of these proinflammatory/proangiogenic Blood was collected from the angiogenesis-induced animals at the indicated time points after tumor challenge. Serum was separated by centrifugation, and levels of tissue inhibitor of metalloproteinases (TIMP) and interleukin (IL)-2 were estimated by the enzyme-linked immunosorbent assay method. All the values are the mean ± standard deviation. AITC = allyl isothiocyanate; PITC = phenyl isothiocyanate. *P < .001 compared with control.
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cytokines-IL-1β, IL-6, TNF-α, and GM-CSF-in angiogenesis-induced untreated control animals were highly elevated 24 hours after tumor challenge, and by day 9, these levels either remained the same (IL-1β) or were much more elevated (IL-6 and TNF-α). AITC and PITC were found to be significantly potent in inhibiting the elevation of these proinflammatory cytokines after angiogenesis induction, and by day 9, the level of proinflammatory cytokines was more or less normalized. This may also have contributed to the reduction of serum VEGF levels of AITC-and PITC-treated angiogenesis-induced animals, as most of these proinflammatory cytokines are good inducers of VEGF. Treatment with AITC and PITC significantly enhanced the serum level of IL-2 in angiogenesisinduced animals compared with untreated control animals. IL-2 was the first cytokine used clinically for treating cancer. 44 It has been reported that IL-2 augments innate immunity by stimulating natural killer cells and also promotes proliferation and differentiation of helper T cells, cytotoxic T cells, and B cells. 45 In vitro experiments using HUVECs have clearly shown that both AITC and PITC could inhibit endothelial cell invasion, migration, proliferation, and tube formation. Treatment with AITC and PITC significantly enhanced the production of TIMP, which is a suppressor of MMP activity, in angiogenesis-induced animals. Vascular remodeling of the ECM-an essential part of angiogenesis-is mediated by MMPs. These proteinases expose new cryptic epitopes in ECM proteins or change their structure, which induces endothelial cell migration. 46 It has been reported that MMPs form minute holes in the sheath-like basement membrane surrounding blood vessels to allow endothelial cells to invade. 47 TIMP directly suppresses the MMP activity, thereby inhibiting ECM remodeling. It also inhibits angiogenic factor-induced endothelial cell proliferation both in vitro and in vivo independent of MMP inhibition. 48 This also contributed to the downregulation of VEGF by AITC and PITC since MMPs are essential for the release and accumulation of VEGF from the cell matrix. 15 All these factors resulted in a significant reduction of endothelial cell migration and invasion by AITC and PITC.
The formation of tubes on matrigel involves endothelial cell attachment, migration, and production of enzymes capable of remodeling the ECM. It has been shown that a reduction in tube formation by endothelial cells was associated with a decrease in the gelatinolytic activities of MMPs, 49 which may be due to enhanced production of TIMP by AITC and PITC. In short, AITC and PITC inhibited the angiogenic differentiation of endothelial cells through the downregulation of proangiogenic factors such as VEGF and proinflammatory cytokines and the upregulation of antiangiogenic factors such as IL-2 and TIMP.
